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Abstract
Background: Colorectal cancer is one of the most common types of cancers worldwide. Recent studies have identified
cancer-initiating cells (CICs) as a subgroup of replication-competent cells in the development of colorectal
cancer. Although it is understood that an inflammation-rich tumor microenvironment presumably supports CIC
functions, the contributory factors are not very well defined. The present study advances our understanding
of the role of the eicosanoids leukotriene D4 (LTD4) and prostaglandin E2 (PGE2) in the tumorigenic ability of
CICs and investigates the consequential changes occurring in the tumor environment that might support
tumor growth.
Methods: In this study we used human HCT-116 colon cancer ALDH+ cells in a nude mouse xenograft model. Protein
expression and immune cell was determined in tumor-dispersed cells by flow cytometry and in tumor sections
by immunohistochemistry. mRNA expressions were quantified using RT-q-PCR and plasma cytokine levels by
Multiplex ELISA.
Results: We observed that LTD4 and PGE2 treatment augmented CIC-induced tumor growth. LTD4-and PGE2-treated
xenograft tumors revealed a robust increase in ALDH and Dclk1 protein expression, coupled with activated β-catenin
signaling and COX-2 up-regulation. Furthermore, LTD4 or PGE2 accentuated the accumulation of CD45 expressing cells
within xenograft tumors. Further analysis revealed that these infiltrating immune cells consisted of neutrophils (LY6G)
and M2 type macrophages (CD206+). In addition, LTD4 and PGE2 treatment significantly elevated the plasma levels of
cysteinyl leukotrienes and PGE2, as well as levels of IL-1β, IL-2, IL-6, TNF-α and CXCL1/KC/GRO. In addition, increased
mRNA expression of IL-1β, IL-6 and IL-10 were detected in tumors from mice that had been treated with LTD4 or PGE2.
Conclusion: Our data suggest that both LTD4 and PGE2 promote CICs in initiating tumor growth by allowing
modifications in the tumor environment. Our data indicate that new therapeutic strategies targeting eicosanoids,
specifically LTD4 and PGE2, could be tested for better therapeutic management of colon cancer.
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Background
Colorectal cancer (CRC) is a major healthcare burden
and the fourth most common cause of cancer-related
deaths in the Western world [1, 2]. The etiological factors
and pathogenic mechanisms underlying the development
of CRC are complex and heterogeneous [3]. Many studies
have demonstrated the pre-existing inflammatory milieu
as the main cause for CRC progression [4]. The best
characterized example for the role of inflammation in
cancer is manifested by inflammatory bowel disease
cases where long-standing inflammation imposes a high
risk of CRC development [5, 6]. Moreover, non-steroidal
anti-inflammatory drugs (NSAIDs) reduce the long-term
risk of cancer death, highlighting the importance of in-
flammation in cancer progression [7]. It is believed that
chronic inflammation facilitates tumor progression by es-
tablishing a milieu that promotes the growth of cancerous
cells. Inflammatory cells recruited to inflammatory foci
can release various pro-inflammatory mediators, including
eicosanoids and cytokines, which can change the micro-
environment to an abnormal milieu. An increase in im-
mune cells can alter the microenvironment so that it
becomes pro-inflammatory and acquires the capability to
change the phenotype of epithelial cells to promote tumor
growth and metastasis [8].
Several studies have demonstrated that eicosanoids,
such as prostaglandins and leukotrienes, are important in-
flammatory mediators in the crosstalk between epithelial
cells and the surrounding stromal cells in the tumor
microenvironment [9, 10]. The importance of COX-2-
derived PGE2 in tumor progression is well proven in
mouse models of CRC [11–13]. PGE2 treatment has been
shown to increase intestinal polyps in both ApcMin/+ mice
and AOM-induced mice [13]. Interestingly, the LTD4 re-
ceptor CysLT1R is highly expressed in human colon can-
cer and correlates negatively with patient survival [14, 15].
Moreover, LTD4 was found to induce proliferation and
survival [16]. By contrast, reduced expression of CysLT2R
is associated with a poor prognosis in patients with CRC,
and CysLT2R signaling promotes apoptosis and differenti-
ation [14, 17]. Taken together, these studies show the key
role of eicosanoids in CRC development.
Over the last decade, the emergence of new therapeutic
targets has improved cancer therapy and has prolonged
the lifespan of these patients. However, initial therapy
and recovery are often complicated by the develop-
ment of relapsed tumors. Cancer-initiating cells (CICs)
are believed to be a small group of tumor cells that
can form tumors [18]. CICs have been identified in
many different tumors such as those in the hematopoietic
system, breast, brain, head, neck, and colon [19–22].
One important characteristic of CICs is their self-
renewal capacity. Therefore, CICs are the most prob-
able cause of tumor chemoresistance and recurrence,
and may be accountable for the current failure of standard
therapies [23, 24].
CICs can be identified by inducing stemness-selective
conditions, or isolated based on the putative expression
of stem cell markers. Multiple cell surface markers like
CD133, CD44, CD24, CD29, CD166 and Lgr5 have been
used by different investigators to isolate CIC subpopula-
tions from colon carcinomas [20, 25–27]. Besides cell
surface markers, the activity of certain pathways or
enzymes is also used to identify stemness in cells. The
activity of aldehyde dehydrogenase 1 (ALDH1), a detoxi-
fying enzyme that oxidizes intracellular aldehydes, has
also been used to identify normal colon stem cells [28].
In a recent study, we showed that ALDH+ cells, com-
pared with other cell surface markers, such as CD133
and CD44, could initiate more colonies than ALDH−
cells, whereas this distinction was not apparent in posi-
tive and negative cells of CD133 and CD44 [29]. This
finding indicates that ALDH activity can be considered a
reliable CIC marker.
Furthermore, in a recent study, we have shown that in-
flammatory lipid mediators can actually enhance the
characteristic properties of CICs under certain condi-
tions in vitro [29].
The aim of the current study was to elucidate whether
enrichment of the tumor microenvironment by inflam-
matory lipid mediators such as LTD4 and PGE2 could
promote the tumorigenic properties of CICs in vivo and
to determine the changes occurring in the tumor envir-
onment that could modify CIC functions.
Methods
Reagents and antibodies
LTD4, PGE2, rabbit anti-human COX-2 and 5-LOX poly-
clonal antibodies were purchased from Cayman Chemical
(Ann Arbor, MI, USA). The ALDEFLOUR (ALDH) kit
was purchased from Stem Cell Technologies (Grenoble,
France). Anti-human CD326 (EpCAM) MicroBeads was
obtained from Miltenyi Biotec (Gladbach, Germany).
Anti-mouse CD45-FITC-conjugated antibody was pur-
chased from Santa Cruz Biotechnology (Santa Cruz, CA).
Anti-mouse LY6G-PE, CD4-PE, and F4/80-PE conjugated
antibodies were purchased from BD Biosciences (Franklin
Lakes, NJ, USA). Anti-mouse CD206-Alexaflour 647
conjugated antibody was obtained from AbD Serotech
(Dusseldorf, Germany). Rabbit anti human β-catenin anti-
body, mouse anti-human ALDH and matrigel basement
membrane matrix were obtained from BD Biosciences
(Franklin Lakes, NJ, USA). The rabbit monoclonal anti-
human Ki67 antibody was obtained from Thermo Fisher
Scientific (Waltham, MA). Rabbit anti-human Dclk1 anti-
body and Rat anti-mouse F4/80 antibody were obtained
from Millipore (Temecula, CA, USA) and AbD serotec
(Raleigh, NC, USA), respectively. All other chemicals were
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of analytical grade and were obtained from Chemicon
International (Temecula, CA) or Sigma Chemical Co. (St.
Louis, MO) unless otherwise stated.
Cell culture
HCT-116 cells (ATCC# CCL-247), derived from human
colon carcinoma, were obtained from the American Type
Culture Collection (ATCC, Manassas, VA). The cells were
maintained in monolayer culture in McCoy’s 5A modified
medium (Gibco BRL, Grand Island, NY) supplemented
with 10 % fetal bovine serum (FBS), 55 μg/ml streptomycin
and 55 IU/ml penicillin. The cells were grown until 5 days
to 70–80 % confluence at 37 °C in a humidified atmos-
phere of 5 % CO2. The cell line tested negative for myco-
plasma (MycoTect® kit, Gibco BRL) at regular intervals.
Flow cytometry
FACS was used to sort the ALDH+ cells from the paren-
tal HCT-116 cell line for xenograft implantation and to
quantify the presence of CD45+ and ALDH+ subpopula-
tions in dissociated tumor cells. For FACS sorting of
ALDH+ cells, HCT-116 cells were harvested using
0.25 % trypsin and 0.02 % EDTA. After resuspension of
the cells in serum-free culture media, the cells were
washed with 0.5 % BSA/PBS and stained with Aldefluor
reagent (Stem Co Biomedical, Durham, NC, USA). The
Aldefluor substrate was added to 1 × 106 cells/ml sus-
pended in Aldefluor assay buffer and incubated at 37 °C
for 40 min. At the same time, cells treated with the spe-
cific ALDH inhibitor diethylaminobenzaldehyde (DEAB)
were stained to serve as the negative control. Cells with
bright fluorescent ALDH signals were detected using a
FACSCalibur or FACSAria flow cytometer (BD Biosci-
ences). The ALDEFLUOR kit was used to sort ALDH+
cells with high ALDH enzymatic activity, as described
previously [29, 30].
For analysis of CD45+ cells, single-cell suspensions
from digested tumors were washed, resuspended in PBS,
counted and divided into 1 × 106 cell aliquots for flow
cytometry. Cells were washed again with 0.5 % BSA/
PBS, resuspended in 100 μl of PBS with 1 % mouse
serum, and incubated at 4 °C for 45 min for Fc-receptor
blocking. Thereafter, each sample was exposed to 5 μl of
anti-mouse CD45-FITC antibody for 45 min at 4 °C in
the dark. Cells were washed with 0.5 % BSA/PBS, resus-
pended in 100 μl of PBS with 0.1 % μg/μl of 7-AAD (BD
Pharmingen), and incubated at 4 °C for 10 min in the
dark. Finally, 400 μl of PBS was added to each sample and
read on a flow cytometer. The analysis was performed
using the Summit v4.6.
Xenograft tumors
The 5- to 6-week-old female nude mice (BalbC nu/nu)
used in this study were purchased from Taconic Europe
A/S (Ry, Denmark). The Regional Ethical Committee for
Animal Research at Lund University, Sweden (M401-12)
approved the animal experiments. To induce subcutane-
ous human colon cancer xenografts, FACS-sorted 1 ×
104 ALDH+ HCT-116 cells were suspended in a 1:1 mix-
ture of PBS:Matrigel (BD Biosciences), and 100 μl of the
mixture was injected subcutaneously into each of both
flanks of the mice. Tumor development was detected by
palpation. The time taken for a palpable tumor to de-
velop was recorded (10–14 days), and the tumor size
was measured every three days using a digital vernier
caliper. Once palpable tumors were established, the mice
were randomly divided into three groups, and then were
treated with vehicle, LTD4 or PGE2. The mice received
daily subcutaneous injections of either ethanol (5 %) as
vehicle, or 24.8 μg/kg/day of LTD4 or 17.6 μg/kg/day of
PGE2. Tumor growth was monitored, and the tumor
volume was estimated every third day. All mice were
sacrificed after 48 days. The tumors were removed, mea-
sured, weighed, and photographed. Tumor tissues were
fixed in 10 % buffered formalin, embedded in paraffin
for immunohistochemistry analysis and/or processed
further for tissue dissociation immediately for FACS ana-
lysis. Tumor volumes were estimated according to the
formula (length × width2)/2.
Dissociation of xenograft tumors
After sacrificing the mice, the excised tumors were
washed with PBS and minced using sterile scalpels. The
minced tumor pieces were resuspended in RPMI medium
supplemented with 10 % FBS and 2 mg/ml Collagenase P
(Roche diagnostics, Basel, Switzerland). The tumor pieces
were further dissociated using the gentleMACS™ Dissocia-
tor for 30 s and incubated at 37 °C for 2 h with rotation.
Afterwards, the cell suspension was filtered through a 70-
μm mesh and washed once with PBS and counted. The
single cells were separated into mouse cells and epithelial
tumor cells using CD326 (EpCAM) microbeads. The
mouse cells and epithelial tumor cells were immediately
stained for CD45, CD4, LY6G, F4/80, CD206 and ALDH,
respectively, for FACS analysis.
Immunohistochemistry
Paraffin-embedded sections obtained from xenograft
tumors were sectioned (4 μm) for immunohistochemi-
cal staining. All procedures were performed using a
Dako automatic slide stainer according to the manufac-
turer’s instructions. Tumor sections were treated with
1–3 % hydrogen peroxide, blocked, and incubated with
anti-ALDH, anti-COX-2 or anti-F4/80 (1:100 dilution
each), anti-Dclk1 or anti-5-LOX (1:200 dilution each),
or anti-β-catenin (1:300). Sections were incubated with
biotinylated secondary antibody, followed by ABC re-
agent (Vector Laboratories Inc., Burlingame, CA).
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Signals were detected using DAB solution (Vector Labora-
tories). Tissues were counterstained with hematoxylin.
The slides were scanned using the Aperio ScanScope CS
system (Aperio Technologies Inc, Vista, CA, USA), and
images were evaluated in a blinded fashion by two inde-
pendent observers.
The immunoreactivity of β-catenin, COX-2, 5-LOX
and F4/80 proteins in the tumor cells was determined
based on the following procedure. Briefly, staining in-
tensity was scored as 0 (negative), 1 (very weak), 2
(weak), 4 (medium) or 6 (strong). The extent of
staining was scored as 0 (0 %), 0.5 (1–5 %), 1 (6–
10 %), 2 (11–20 %), 3 (21–30 %), 4 (31–40 %), 5
(41–50 %), 6 (51–60 %), 7 (61–70 %), 8 (71–80 %), 9
(81–90 %) and 10 (91–100 %) according to the per-
centage of the positive staining area in relation to the
whole carcinoma area. Next, the sum of the intensity
score and extent score was regarded as the final
staining scores for COX-2, 5-LOX, F4/80 and β-
catenin proteins.
CysLTs, PGE2 and cytokine ELISA analysis
Blood was collected by cardiac puncture at the time of
animal sacrifice, and a nonselective COX inhibitor, indo-
methacin, was immediately added to the blood sam-
ples together with the anticoagulant sodium citrate. The
plasma was separated by spinning the samples at 5000 ×
g for 4 min. CysLTs and PGE2 plasma samples were
measured using a competitive enzyme immunoassay ob-
tained from Enzo Life Sciences (Solna, Sweden). All
measurements were performed according to the manu-
facturer’s instructions.
Plasma cytokines were analyzed using a multiplex
sandwich immunoassay format and the electro-
chemiluminescence MSD ultrasensitive proinflammatory
multiplex kit (Meso-Scale Discovery, Gaithersburg, MD).
The MSD multispot array was run according to the manu-
facturer’s protocol. Briefly, 96-well plates pre-coated with
capture antibodies for TNFα, IL-1β, IL-2, IL-4, IL-6, IL-10
and CXCL1/KC/GRO, INFγ were incubated with plasma
samples for 2 h. Subsequently, detection antibodies were
added, and the plate was incubated for another 2 h.
After washing, the plate was read using an MS2400
imager (MSD).
Real-Time quantitative PCR
qPCR reactions employing TaqMan gene expression assays
were used to measure tumor tissue expression of CysLT1R
(Hs00272624_s1), PTGER2 (Hs00168754_m1), PTGRR4
(Hs00168761_m1), Arginase 1 (Mm00475988_m1), IL-1β
(Mm00434228_m1; Hs00174097_m1), IL-6 (Mm004461
90_m1; Hs00985639_m1) and IL-10 (Mm01288386_m1)
genes (Applied Biosystems, Cambridge, United Kingdom)
as described earlier [29].
Statistical analysis
Statistical analysis was performed using GraphPad Prism
5 software. Results are expressed as the mean ± SEM.
All comparisons between the mean values were per-
formed using either one-way analysis of variance
(ANOVA) with Newman-Keuls post-hoc test, two-way
ANOVA, or Student’s unpaired t test wherever applic-
able. P values less than 0.05 were considered to indicate
statistical significance.
Results
Both LTD4 and PGE2 affect the tumorigenic potential of
ALDH+ cells
In a recent in vitro study, we showed that an ALDH+
subpopulation of colon cancer cells is enriched with
properties of cancer-initiating cells, and is increased
two-fold in the presence of inflammatory lipid mediators
such as LTD4 or PGE2 [29]. In this study we also investi-
gated and observed that treatment with these two lipid
mediators for 39 weeks increased tumor growth in a
xenograph model [29]. To further study the effect of the
microenvironment on the in vivo tumorigenicity of
ALDH+ cells in the presence of LTD4 or PGE2, we
injected HCT-116 ALDH+ cells in both flanks of nude
mice. The mice received daily treatment of LTD4 or
PGE2 to create an inflammation-enriched tumor micro-
environment for a period of 48–49 days. Tumor growth
was monitored every three days until the experimental
endpoint after 48–49 days. As shown in Fig. 1, panel b,
both LTD4 and PGE2 treatments significantly enlarged
the tumor volume compared with the vehicle (ethanol)-
treated ALDH+ group, results similar to those previously
reported [29]. In addition, the tumor weight was signifi-
cantly increased in both LTD4- and PGE2-treated mice
compared with the vehicle-treated ALDH+ group (Fig. 1,
panel d). Taken together, our data on the tumor growth,
their size and weight indicated that both LTD4 and PGE2
could modulate the tumor environment of ALDH+ cells
in favor of augmented tumor growth.
Both LTD4 and PGE2 stimulation increase the percentage
of ALDH+ cells and Dclk1, β-catenin and COX-2 protein
expression
Furthermore, to ascertain how LTD4 or PGE2 facilitates
tumor growth, we examined the percentage occurrence of
different cell types, particularly CICs, within HCT-116
ALDH+ cell tumor sections. Interestingly, mice treated
with LTD4 or PGE2 showed significantly higher percentage
of ALDH+ cells in their tumors compared with the
vehicle-treated ALDH+ group by FACS (Fig. 2, panel a).
Similarly, increased protein expression of ALDH was seen
in IHC sections of both LTD4 and PGE2 treated tumors of
mice compared to control group (Fig. 2, panel b). More-
over we also found increased expression levels of the
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Dclk1 protein, an intestine cancer stem cell marker [31],
within tumor sections from both LTD4- and PGE2- treated
mice (Fig. 2, panel c). Further, to identify the factors influ-
encing the LTD4- or PGE2-elicited tumor growth, we ex-
amined the protein level of β-catenin, COX-2, and 5-LOX.
As summarized in Fig. 2 panel d and e, in vehicle-treated
tumor sections, β-catenin was localized predominantly in
the plasma membrane. However, both LTD4- and PGE2-
treated tumors demonstrated significantly higher cytoplas-
mic β-catenin levels and increased nuclear localization
than the control vehicle group. Furthermore, the COX-2
levels were significantly augmented in mice treated with
LTD4 or PGE2 (Fig. 2, panel e). 5-LOX protein expression
was not found to be significantly changed in mice treated
with either LTD4 or PGE2 compared with the control
vehicle group (Additional file 1: Fig. S1).
Effect of LTD4 or PGE2 treatment on immune cells
Moreover, tumors from mice treated with LTD4 or PGE2
revealed by FACS analysis significantly increased per-
centage of CD45+ mouse cells compared with tumors
from vehicle-treated mice (Fig. 3, panel a). Double stain-
ing of CD45+ cells for other immune cells markers re-
vealed increased percentage of LY6G+ cells, neutrophils
(Fig. 3, panel b), and CD4+ cells (Fig. 3, panel c). Further
FACS analysis with double staining of CD45+ cells and
macrophage marker F4/80 revealed increased percentage
of macrophages in both LTD4- and PGE2-treated mice
groups (Fig. 4, panel a). Because we observed by FACS
analysis that LTD4- and PGE2-treated mice had an in-
creased percentage of F4/80+ cells, we further analyzed
the tumor sections by IHC examining the level of F4/80.
We observed a significant increase in F4/80 protein ex-
pression in both the LTD4- and PGE2-treated groups
compared with the control vehicle group (Fig. 4, panel
b). Additionally, FACS gating F4/80 cells for CD206+ (a
M2 macrophage marker) revealed increased percentage
of CD206+ cells in tumors from mice treated with LTD4
or PGE2 compared with tumors from control mice (Fig. 4,
panel c). We also detected increased arginase 1 (known to
be highly expressed in M2 macrophages) expression in tu-
mors from mice treated with LTD4 and PGE2 (Fig. 4, panel
d), which corroborates our FACS data. These results pro-
vide support for a positive correlation between immune
cells populating the tumor and CICs.
Both LTD4 and PGE2 treatment increase IL-1 and IL-6
mRNA and cytokine secretion
We next investigated the tumor mRNA expression of
some key cytokines, we observed significantly increased
Fig. 1 Effect of LTD4 and PGE2 on xenograft tumor growth initiated by ALDH
+ HCT-116 cells. Mice were injected subcutaneously with 1 × 104 ALDH+
HCT-116 cells into two flanks and received subcutaneous injections of vehicle (5 % ethanol in PBS), LTD4 (24.8 μg/kg/day) or PGE2 (17.6 μg/kg/day)
from the third week onwards daily. a Images of xenograft mice with representative tumor sizes upon daily administration of either ethanol, LTD4 or
PGE2 at day 48. b Graph showing tumor volume for the mice treated with vehicle (ethanol), LTD4 or PGE2. c Representative tumor images from treated
groups at the experimental end-point, day 48. d Tumor weights of the LTD4- and PGE2-treated groups compared with the vehicle group
at the end-point, day 48. The data shown are the means ± SEM, n = 6 mice in each group. *P < 0.05, **P < 0.01
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Fig. 2 (See legend on next page.)
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expression levels of IL-1β, and IL-6 in tumors from mice
treated with LTD4 or PGE2 compared to vehicle treated
mice (Fig. 5, panel a). Furthermore, mice treated with
LTD4 showed increased IL-10 expression in their tumors
compared to tumors from control mice. This increase in
IL-10 tumor expression was not noticed in tumors from
mice treated with PGE2. Furthermore, we analyzed dif-
ferent cytokine levels from murine plasma. In good
agreement with our data on mRNA cytokine levels, we
observed significantly increased in the plasma concen-
trations of IL-1β and IL-6 in both LTD4 and PGE2
treated mice compared with the controls and for IL-10
(See figure on previous page.)
Fig. 2 FACS analysis and immunohistochemistry of xenograft ALDH+ HCT-116 cell tumors treated with LTD4 or PGE2. a Representative dot plots
and corresponding graphs of FACS analysis of the percentage of ALDH+ cells in dissociated tumors from vehicle (ethanol), LTD4 or PGE2 treated
groups respectively. b–e Immunohistochemical analysis of ALDH, Dclk1, β-catenin, and COX-2 protein expression levels. The tumors from
vehicle- (ethanol), LTD4- and PGE2-treated mice were processed for immunohistochemical analysis. Representative images (40×) and corresponding
bar graphs show staining scores of (b) ALDH, (c) Dclk1, (d) β-catenin, and (e) COX-2 proteins in tumors. The final scores represent the
sum of the staining intensity and staining percentage within tumor areas. The data are expressed as means ± SEM, n = 6 mice in each
group. *P < 0.05, **P < 0.01 and ***P < 0.001
Fig. 3 FACS analysis of xenograft ALDH+ HCT-116 cell tumors treated with LTD4 or PGE2. a–c Representative dot plots and corresponding graphs
of FACS analysis of the percentage of CD45+ cells in dissociated tumors from vehicle (ethanol), LTD4 or PGE2 treated groups respectively. a CD45
+,
(b) LY6G, and (c) CD4+ cells in dissociated tumors from vehicle (ethanol), LTD4 or PGE2 treated groups respectively. The data are expressed as means
± SEM, n = 6 mice in each group. *P < 0.05, **P < 0.01 and ***P < 0.001
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Fig. 4 FACS and immunohistochemistry analysis of LTD4- or PGE2-treated xenograft mice tumors. a Representative dot plots and corresponding
graphs of FACS analysis of the percentage of CD45+ and F4/80+ double positive cells in dissociated tumors from vehicle (ethanol), LTD4 or PGE2
treated groups respectively. b Representative immunohistochemistry images (40×) of F4/80 and their corresponding bar graphs show overall F4/
80 scores within tumors. The final scores represent the sum of the staining intensity and staining percentage within the tumor area. c Representative
dot plots and corresponding graphs of FACS analysis of the percentage of F4/80+ and CD206+ double positive cells in dissociated tumors from vehicle
(ethanol), LTD4 or PGE2 treated groups respectively. d Relative mRNA expression of arginase 1 in tumors of mice treated with LTD4 or PGE2. The
analyzed data are expressed as means ± SEM, n = 6 mice in each group. *P < 0.05 and **P < 0.01
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in LTD4 treated mice (Fig. 5, panel b). TNF-α levels were
significantly increased in PGE2-treated mice, whereas
only a modest increase was noticed in LTD4-treated
mice compared with the vehicle-treated group. In
addition, LTD4 treatment significantly augmented the
CXCL1/KC/GRO plasma levels compared with vehicle
treatment, while PGE2 treatment did not show any effect
on the CXCL1/KC/GRO levels. Interestingly, both LTD4-
and PGE2-treated mice showed a decreased level of
IFN-γ compared with the control (Fig. 5, panel b). We
also examined whether the plasma levels of eicosanoids
were altered in LTD4- and PGE2-treated mice. Concor-
dantly, the plasma levels of CysLTs and PGE2 were
found to be significantly increased in both LTD4- and
PGE2-treated mice compared with the control vehicle
group (Fig. 5, panel c).
Fig. 5 Effect of LTD4 or PGE2 on the levels of different cytokines and eicosanoids in xenograft ALDH
+ HCT-116 cell tumor mice. a mRNA expression of
cytokines (IL-1β, IL-6 and IL-10) in tumors of mice treated with vehicle, LTD4 or PGE2. b Plasma levels of cytokines (IL-1β, IL-2, IL-6, TNF-α, CXCL1, IL-10
and IFN-γ) from vehicle- (ethanol), LTD4- or PGE2-treated xenograft mice. c Plasma levels of CysLTs and PGE2 from vehicle, LTD4- or PGE2-treated
xenograft mice. The results are expressed as means ± SEM, n = 6 mice in each groups. *P < 0.05 and **P < 0.01
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Both LTD4 and PGE2 treatment increase plasma CysLTs
and PGE2 secretion
As we observed that both LTD4 and PGE2 drastically in-
duced inflammatory cell infiltration as well as COX-2
up-regulation, we next investigated if LTD4 and PGE2
triggered an increased expression of their respective re-
ceptors, CysLTR1 (CYSLT1R), EP2 (PTGER2) and EP4
(PTGER4). FACS sorted ALDH+ and ALDH− HCT-116
were incubated with LTD4 or PGE2 for 48 h after which
we examined the mRNA levels of their respective recep-
tors. CysLTR1 expression was found to be increased in
ALDH+ cells compared to ALDH− cells. Treatment with
LTD4 or PGE2 increased CysLTR1 expression in both
ALDH+ and ALDH−HCT-116 cells although the levels
were significantly higher in ALDH+ HCT-116 cells
(Fig. 6, panel a). A similar difference in EP2 receptor
Fig. 6 Effect of LTD4 or PGE2 on CysLTR1, EP2, EP4, IL-1β, and IL-6 in ALDH− and ALDH+ HCT-116 cells. a–c mRNA receptor expression
of (a) CYSLT1R, (b) PTGER2 (EP2), (c) PTGER4 (EP4), (d) IL-1β and (e) IL-6 mRNA expression in ALDH− and ALDH+- HCT-116 cells with vehicle (ethanol),
10 μM of LTD4 or PGE2 treatment. The results are expressed as means ± SEM, n = 6 mice in each groups. *P < 0.05
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expression was noticed between ALDH+ and ALDH−
cells, but the effects of PGE2 or LTD4 treatment was
much more pronounced in ALDH+ cells (Fig. 6, panel
b). EP4 receptor expression also showed a similar trend
of increase as the EP2 receptor expression in ALDH+
cells compared to ALDH− cells, however PGE2 or LTD4
treatment had a trend but no clear effect on EP2 recep-
tor expression in neither ALDH+ or ALDH− cells (Fig. 6,
panel c). We also examined the effect on IL-1β and IL-6
mRNA levels in these settings (Fig. 6, panel d and e).
Interestingly, we found a statistical significant increase
in IL-1β mRNA levels in ALDH+ cells compared to
ALDH− cells (Fig. 6, panel d), which indicated the im-
portance of IL-1β in CIC. Furthermore, we found a more
pronounced effect of LTD4 and PGE2 stimulation in
ALDH+ cells compared to ALDH− cells of the IL-6
mRNA levels, however no statistical difference between
ALDH+ and ALDH− cells was seen (Fig. 6, panel e).
Discussion
CICs, which represent a small population of cancer cells
with tumor initiating/stem-like properties, are widely
recognized as a significant contributor of CRC develop-
ment and progression [32]. However, the mechanisms
whereby CICs promote tumor growth are largely un-
known. Nonetheless, it is presumed that CICs functions
are predominantly impacted by their surrounding micro-
environment enriched with several mediators, including
inflammatory lipid molecules. The present study investi-
gated this possibility to develop a better understanding
of the role of the inflammatory lipid mediators LTD4
and PGE2 in CIC tumor growth [29].
In this study, we demonstrated that the inflammatory
mediators LTD4 and PGE2 augmented tumor growth in
mice injected with ALDH+ HCT-116 cells, CICs, a find-
ing that is consistent with that in our previous study
[29]. Our results show that high ALDH-expressing colon
cancer cells show all characteristics of CICs under both
in vivo and in vitro conditions. Additionally, these cells
were shown to have increased cancer stem cell charac-
teristics in the presence of the inflammatory mediators
LTD4 and PGE2 [29]. Consistent with this finding, we
also observed that the tumor-forming ability of ALDH-
sorted CICs was increased markedly with LTD4 or PGE2
treatment in nude mice. In addition, we noted that
ALDH+ HCT-116-sorted CICs have higher tumor-
initiating ability than parental cells because the onset of
tumors was quicker in mice injected with ALDH+ HCT-
116 sorted cells than in mice injected with parental cells.
LTD4 and PGE2 are known to mediate their responses
on colon cancer cells through activation of their recep-
tors, CysLTR1 and EP1-4 [33–35]. Interestingly, we have
found that CICs (ALDH+) expressed high levels of
CysLT1R, EP2 and EP4 receptors and the expression
levels of CysLT1 and EP2 receptors were further in-
creased in the presence of LTD4 and PGE2. These data
are in good agreement with our previous findings that
the abilities of LTD4 or PGE2 to promote CIC-induced
colony growth is suppressed in the presence of their
receptor antagonist [29].
Another in vivo property of CICs is their self-expansion
in tumors, and we investigated whether LTD4 or PGE2
drives the self-expansion of ALDH-sorted cells in tumors.
Interestingly, we observed that ALDH proteins were
highly expressed in tumors from mice receiving either
LTD4 or PGE2, further substantiating our previous notions
that both of these inflammatory mediators play an import-
ant role in driving CIC expansion [29]. It was also note-
worthy here that the stimulatory effect of the LTD4 or
PGE2 on CIC content was not restricted merely to
ALDH-marked cells but to stimulation of the expansion
of different CIC markers with similar potency. We cross-
checked the data by detecting changes in Dclk1 protein,
which is an exclusive marker for cancer stem cells of the
intestine. The tumorigenic properties of Dclk1-marked in-
testinal cancer stem cells have been proven in ApcMin/+,
suggesting their role in CRC [31].
To identify the potential factors that could be involved
in tumor growth induced by LTD4 or PGE2, we exam-
ined some key proteins such as β-catenin, COX-2 and 5-
LOX, which are strongly associated with colon cancer
cell proliferation and CRC progression [16, 29]. LTD4
was demonstrated to trigger the nuclear accumulation of
β-catenin in colon cancer cells in vitro, a finding that is
linked to the simultaneous up-regulation of COX-2 [16]
and the effect of LTD4 on proliferation [16]. With this
in mind, we examined whether LTD4 or PGE2 could
modify β-catenin signaling in CIC-induced tumors in
vivo. Interestingly, we observed a high percentage of β-
catenin accumulated in the cytoplasm and nuclear frac-
tions of tumor cells of mice treated with LTD4 and PGE2.
Increased levels of active β-catenin lead to its transloca-
tion from the cytosol to the nucleus where it can activate
the TCF/LEF family of transcription factors [36]. These
transcription factors, in turn, regulate several genes associ-
ated with carcinogenesis, such as cyclin D1, c-myc, and
COX-2 [16]. Interestingly, we detected significantly high
COX-2 protein expression within the tumors of mice
treated with LTD4 or PGE2. Elevated COX-2 levels have
been demonstrated in all constituent cells of neoplastic
colon tissue compared with normal colon tissues [37].
COX-2 overexpression confers resistance to apoptosis and
facilitates cell proliferation, which can, together, aggravate
a cell’s tumorigenic potential [38–40].
Taken together, our data suggest that inflammatory
mediators encourage CICs to evoke tumor growth, pos-
sibly by stimulating β-catenin signaling, and concurrent
up-regulation of COX-2 as well as proliferation.
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Lipid inflammatory mediators, particularly leukotri-
enes, also play crucial role in leukocyte chemoattraction
by the induction of rapid invasion and recruitment of in-
flammatory cells to the plasma membrane of endothelial
cells [10]. Thus, inflammatory cells might be partly in-
volved in driving tumor growth in mice treated with
LTD4 or PGE2. To explore this possibility, we examined
the CD45+ cell count in tumors of mice receiving LTD4
or PGE2 treatment. It was noted that both LTD4 and
PGE2 treatment intensified the percentage of CD45
+ cells
in the tumors, with a concurrent increase in ALDH+ cells.
Furthermore, we found high levels of F4/80-positive
staining, representing the total macrophage population
within the tumor. In the tumor microenvironment,
macrophages play an important role being highly
enriched within the tumor as well as in the tumor
stroma and secreting many factors known to induce
neoplasia [41]. Tumor-associated macrophages (TAMs)
play an important role in cancer progression; accord-
ingly, high levels of macrophage infiltration into the
tumor tissues are associated with a poor prognosis in
cancer patients [42, 43]. These macrophages play a crucial
role in tumor immunity and possess potent immunosup-
pressive functions that contribute to tumor growth. Mac-
rophages were also demonstrated to produce a wide array
of cytokines, prostaglandins and leukotrienes [43, 44]. We
also found that LTD4- and PGE2-treated mice had higher
plasma levels of CysLTs and PGE2, possibly derived from
tumor associated macrophages.
In addition, we found significantly higher plasma levels
of proinflammatory cytokines IL-1β, IL-2, IL-6 in both
LTD4- and PGE2-treated mice. A significant increase in
TNF-α levels was also detected with PGE2 treatment.
TNF-α, IL-1, and IL-6 have been demonstrated to pro-
mote colorectal and colitis-associated tumor development
[45]. Interestingly, TNF-α is known to induce β-catenin
nuclear accumulation without APC mutations in gastric
tumors [46]. Thus, an increased cytokine level could be a
possible explanation for driving the increased nuclear ac-
cumulation of β-catenin observed in tumors of mice
treated with LTD4 or PGE2. Furthermore, increased levels
of the chemokine CXCL1/KC/GRO were found in mice
treated with LTD4. CXCL1/KC/GRO was shown to recruit
and activate murine neutrophils and could modify tumor
growth by numerous mechanisms [47]. One interesting
finding here is that mice receiving LTD4 or PGE2 dis-
played an increased plasma level of IL-10 and a decreased
level of IFN-γ. This finding is interesting, particularly
because IL-10 is known to inhibit IFN-γ, which has an
anti-tumor effect [48]. High production of IL-10 is also a
characteristic feature of tumor-associated/M2 macro-
phages, adapted to suppress immune responses against
tumors [43, 49]. These data fits well with our present find-
ing that LTD4 as well as PGE2 greatly enhanced tumor
infiltration by M2 macrophages (recognized by CD206
positive staining) and by increased tumor expression of
arginase1. Interestingly, the tumor infiltration of M2
macrophages coincide with an increased tumor expres-
sion of the IL-10 in tumors from animals treated with
either of the two lipid mediators. In fact, our data sup-
port a notion whereby the infiltrating macrophages
within the tumor might have acquired a phenotype
characterized by a high production of IL-10, which sup-
presses the anti-tumor actions of IFN-γ and encourages
tumor growth. Overall, our data strongly support a tight
correlation between host systemic immune responses and
tumor growth.
Conclusions
We have shown that the lipid inflammatory mediators
LTD4 and PGE2 not only stimulated CICs to self-expand
but also induced several changes in the CIC tumor micro-
environment, which cumulatively drives tumor growth
from CICs. This finding deserves considerable attention,
and future research should focus not only to target CICs
but also associated inflammatory lipid mediators to design
more effective therapies for colon cancer prevention.
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